ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Summary

Preclinical work demonstrates that inhibiting ATP citrate lyase (ACLY) enhances anti-tumor immunity and suppresses liver cancer in the MASH-HCC context. The study positions ACLY as an immunometabolic target capable of reprogramming an immunosuppressive tumor microenvironment.

Key Findings

• ACLY inhibition enhanced anti-tumor immunity within an immunosuppressive microenvironment characteristic of MASH-HCC.
• Preclinical ACLY targeting suppressed liver cancer growth.
• The study establishes ACLY as a therapeutically actionable immunometabolic node.

Clinical Implications

Suggests ACLY inhibition as a candidate strategy to enhance responsiveness to immunotherapy and suppress tumor growth in MASH-HCC. If translated, it could expand options for metabolic liver cancer therapy.

Limitations

• Preclinical data; human efficacy and safety remain untested
• Details of models and breadth of validation are not provided in the abstract snippet

Future Directions

Conduct translational and early-phase clinical trials testing ACLY inhibitors in MASH-HCC, potentially in combination with checkpoint blockade; dissect immune cell subsets and metabolic rewiring mediating benefit.